A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980

Current concepts in mild cognitive impairment

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781

Mild cognitive impairment

Gauthier, S. G., Reisberg, ‌., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials

Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972

Prevalence of mild cognitive impairment is higher in men

Petersen, R. C., Roberts, R. O., Knopman, D. S., Geda, Y. E., Cha, R. H., Pankratz, V. S., Boeve, B. F., Tangalos, E. G., Ivnik, R. J., & Rocca, W. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f11d85 · Cited by 771

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial

Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764

Ginkgo biloba for Prevention of Dementia A Randomized Controlled Trial

DeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 683

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643

Neuropathologic Features of Amnestic Mild Cognitive Impairment

Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.665 · Cited by 616

Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease

Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513

Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia

Jicha, G. A., Parisi, J. E., Dickson, D. W., Johnson, K., Cha, R., Ivnik, R. J., Tangalos, E. G., Boeve, B. F., Knopman, D. S., Braak, H., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.674 · Cited by 399

Early Detection and Differential Diagnosis of Alzheimer’s Disease and Depression with Neuropsychological Tasks

Swainson, R., Hodges, J. R., Galton, C. J., Semple, J., Michael, A., Dunn, B. D., Iddon, J. L., Robbins, T. W., & Sahakian, B. J. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051269 · Cited by 375

Subtype of Mild Cognitive Impairment and Progression to Dementia and Death

Yaffe, K. S., Petersen, R. C., Lindquist, K. J., Kramer, J. H., & Miller, B. L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095427 · Cited by 339

The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment

Collie, A., & Maruff, P. T. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(00)00012-9 · Cited by 339

Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials

Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040338 · Cited by 330

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer’s Disease

Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata‐Fukae, C., Li, H.-F., Feng, L., Lecanu, L., Walker, B. R., Planel, E., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130526 · Cited by 221

Episodic and semantic memory in mild cognitive impairment

Dudas, R. B., Clague, F., Thompson, S., Graham, K. S., & Hodges, J. R. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.12.005 · Cited by 190

Annual Rate and Predictors of Conversion to Dementia in Subjects Presenting Mild Cognitive Impairment Criteria Defined according to a Population-Based Study

Amieva, H., Letenneur, L., Dartigues, J., Rouch‐Leroyer, I., Sourgen, C., d'Alché-Birée, F., Dib, M., Barberger‐Gateau, P., Orgogozo, J., & Fabrigoule, C. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000077815 · Cited by 187

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 164

NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP)

Gozes, I., Morimoto, B. H., Tiong, J., Fox, A. W., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P. E., Aisen, P. S. S., et al. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00053.x · Cited by 144

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model

Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N., Rosenmann, H., & Gozes, I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.011 · Cited by 122

‘Prodromal Alzheimerʼs disease’: a more useful concept than mild cognitive impairment?

Dubois, B. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200008000-00001 · Cited by 76

NAP, A Neuroprotective Drug Candidate in Clinical Trials, Stimulates Microtubule Assembly in the Living Cell

Gozes, I., & Divinski, I. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018208 · Cited by 71

A Novel Signaling Molecule for Neuropeptide Action: Activity‐dependent Neuroprotective Protein

Gozes, I., Bassan, M., Zamostiano, R., Pinhasov, A., Davidson, A., Giladi, E., Perl, O., Glazner, G. W., & Brenneman, D. E. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07884.x · Cited by 70

A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment

Gómez‐Isla, T., Blesa, R., Boada, M., Clarimón, J., del Ser, T., Domènech, G., Ferro, J. M., Gómez‐Ansón, B., Manubens, J. M., Martínez‐Lage, J. M., et al. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181611024 · Cited by 65

NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)

Gozes, I., Divinski, I., & Piltzer, I. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s3 · Cited by 62

Activity-dependent neurotrophic factor (ADNF)

Gozes, I., & Brenneman, D. E. (1996) · Journal of Molecular Neuroscience · doi:10.1007/bf02737061 · Cited by 61

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The Alzhemedtm (Tramiprosate) experience

Saumier, D., Aisen, P. S. S., Gauthier, S. G., Vellas, B. J., Ferris, S. H., Duong, A., Suhy, J., Oh, J., Lau, W. C., Garceau, D., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0047-4 · Cited by 34

Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial

Aisen, P., Thal, L. J., Ferris, S. H., Assaid, C. A., Nessly, M. L., Giuliani, M., Lines, C., Norman, B., & Potter, W. Z. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884602 · Cited by 32

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy

Zemlyak, I., Manley, N. C., Vulih, I., Cutler, A. B., Graber, K., Sapolsky, R. M., & Gozes, I. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06415.x · Cited by 24

Activity-dependent neuroprotective protein–derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse

Sari, Y. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.021 · Cited by 23

The influence of the peptide NAP on Mac-1-deficient mice following closed head injury

Zaltzman, R., Alexandrovich, A. G., Trembovler, V., Shohami, E., & Gozes, I. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.014 · Cited by 22

NAP protects against cyanide-related microtubule destruction

Zemlyak, I., Sapolsky, R. M., & Gozes, I. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0252-7 · Cited by 14

The Wechsler memory scale-III: Validity and reliability

Uttl, B., & Graf, P. (1999) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/14.8.705a · Cited by 8

Development and validation of neuropsychological LD subtypes with radically diverse children

Crews, K. J., Hatten, K. C., D’Amato, R. C., & Pelletier, S. L. F. (1999) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/14.1.4a · Cited by 2

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676

Current and Future Treatments in Alzheimer Disease: An Update

Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966

Alzheimer’s disease: Recent treatment strategies

Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547

Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review

Reitz, C. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/369808 · Cited by 398

Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting

Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306

P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

Schmechel, D. E., Gerard, G., Vatakis, N. G., Harper, L., Ross, J., Bari, M. A., Walling, D. P., Stedman, M., Winston, J. L., Morimoto, B. H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1455 · Cited by 13

Improved memory with AL 108 in mild cognitive impairment

&NA; (2008) · Inpharma Weekly · doi:10.2165/00128413-200816510-00001

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 458

P4‐201: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2A CLINICAL TRIAL OF NA‐831 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Tran, B. H., & Tran, L. L. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.07.022

Multicenter research on efficacy and tolerance of memantine in Chinese patients with Alzheimer's disease

Tang, H. (2007)